Systemic Treatment Strategies and Outcomes of Patients With Synchronous Peritoneal Metastases of Gastric Origin: A Nationwide Population-Based Study.

Niels A D GuchelaarBo J NoordmanMarion W WeltenMyron T van SantenMicha J de NeijsStijn L W KoolenRob H A VerhoevenEsther Oomen-de HoopPieter C van der SluisSjoerd M LagardeHanneke W M van LaarhovenIgnace H J T de HinghGeert-Jan CreemersBianca MostertBas P L WijnhovenRon H J Mathijssen

Published in: Journal of the National Comprehensive Cancer Network : JNCCN (2024)

There is substantial heterogeneity in systemic treatment choices in patients with gastric cancer and peritoneal metastases in the Netherlands. In this study, patients treated with triplets containing docetaxel and with trastuzumab-containing regimens survived longer than patients who received doublet therapy. Despite this, median OS for all treatment groups remained below one year.

Keyphrases

stem cells
single cell
epidermal growth factor receptor

type diabetes
radiation therapy
replacement therapy

mesenchymal stem cells
bone marrow

locally advanced
rectal cancer